Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hilary Shmeeda

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|June 6, 2007
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicinAlberto Gabizon, Rut Isacson, Ora Rosengarten, et al.
Molecular Cancer Therapeutics|May 2, 2006
Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptorsHilary Shmeeda, Lidia Mak, Dina Tzemach, et al.
Seminars in Cancer Biology|December 25, 2019
Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatmentNinh M La-Beck, Xinli Liu, Hilary Shmeeda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing miceAlberto Gabizon, Aviva T Horowitz, Dorit Goren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomesAlberto A Gabizon, Dinah Tzemach, Aviva T Horowitz, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapyAlberto Gabizon, Patricia Ohana, Yasmine Amitay, et al.
Cancer Chemotherapy and Pharmacology|September 26, 2009
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor modelsAlberto Gabizon, Dina Tzemach, Jenny Gorin, et al.
Molecular Pharmaceutics|January 4, 2017
Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron MicroscopyXiaohui Wei, Yogita Patil, Patricia Ohana, et al.
Pharmaceutical Research|November 18, 2015
Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in TissuesYasmine Amitay, Hilary Shmeeda, Yogita Patil, et al.
Investigational New Drugs|January 20, 2020
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patientsAlberto A Gabizon, Esther Tahover, Talia Golan, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|June 6, 2007
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicinAlberto Gabizon, Rut Isacson, Ora Rosengarten, et al.
Molecular Cancer Therapeutics|May 2, 2006
Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptorsHilary Shmeeda, Lidia Mak, Dina Tzemach, et al.
Seminars in Cancer Biology|December 25, 2019
Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatmentNinh M La-Beck, Xinli Liu, Hilary Shmeeda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing miceAlberto Gabizon, Aviva T Horowitz, Dorit Goren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomesAlberto A Gabizon, Dinah Tzemach, Aviva T Horowitz, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapyAlberto Gabizon, Patricia Ohana, Yasmine Amitay, et al.
Cancer Chemotherapy and Pharmacology|September 26, 2009
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor modelsAlberto Gabizon, Dina Tzemach, Jenny Gorin, et al.
Molecular Pharmaceutics|January 4, 2017
Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron MicroscopyXiaohui Wei, Yogita Patil, Patricia Ohana, et al.
Pharmaceutical Research|November 18, 2015
Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in TissuesYasmine Amitay, Hilary Shmeeda, Yogita Patil, et al.
Investigational New Drugs|January 20, 2020
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patientsAlberto A Gabizon, Esther Tahover, Talia Golan, et al.
Pageof 4